

Data Sharing Statement

Article Info	https://dx.doi.org/10.21037/atm-21-1803	
Item	Question	Authors' Response (place "-" if not applicable)
1	Would you like to share data collected for your study to others?	Yes
2	If not, would you like to share the reason for your decision?	-
3	What data in particular will be shared?	The transition probabilities derived from survival curves of the clinical trial will be shared.
4	Any other documents will be shared? Such as study protocol, statistical analysis plan, informed consent form, clinical study report, analytic code.	-
5	When will data availability begin?	From the publication date.
6	When will data availability end?	2 years within the publication date.
7	To whom will you share the data?	Researchers in the field of economic evaluation and oncology who are interested in this study
8	For what type of analysis or purpose?	For analysis to evaluated the economic and clinical value of camrelizumab.
9	How or where can the data/documents be obtained?	Emails could be sent to the listed email address below: yangfan512@njmu.edu.cn
10	Any other restrictions?	Potential benefits and risks would be balanced by the author group on the requests of data sharing.